MPR

MPR provides daily drug news and industry-supported drug information & education. Download our drug reference and clinical tools app today!

[MPR @eMPR]

From ACR '26: Combining individualized depression pharmacotherapy with olokizumab and conventional synthetic DMARDs demonstrates superior clinical improvement compared with conventional therapy alone. https://t.co/91d7Q4kRJ4

[MPR @eMPR]

Sunharbo has been approved to reduce the risk of stroke in adults with recent noncardioembolic ischemic stroke or high-risk transient ischemic attack. https://t.co/hEH2ydsytF

[MPR @eMPR]

Sight-loss warning to be added to the prescribing information of GLP-1 RAs. https://t.co/xLlvqlS0sY

[MPR @eMPR]

ACR 2026: The odds of an adverse drug event in patients with autoimmune rheumatic diseases is strongly associated with supportive care and symptom-directed therapies. https://t.co/oYeQ3cGFfy

[MPR @eMPR]

Study assesses real-world patient experiences with lemborexant, including perceived benefits, side effects, and overall treatment satisfaction. https://t.co/zYyaSrdngF

[MPR @eMPR]

🗣️ New MPR pod!
😴 Insomnia Tx for peds moves closer;
🧬 Gene therapy for Huntington disease;
🔴 Vadadustat dosed 3 times per week trial for anemia due to CKD;
✅ Voceryq granted accelerated approval for RRP; &
📋 New application for zanubrutinib in MCL.
https://t.co/cghteRE7P0

[MPR @eMPR]

Rybrevant Faspro approved for recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. https://t.co/Kzk0FrVKRS

[MPR @eMPR]

🎃 Wishing all our readers a very Happy Halloween! 👻

[MPR @eMPR]

📣 Latest pod out now! This week:
🔹 Ultomiris gains accelerated approval;
💉 Alzheimer vaccine Fast Tracked;
🔸 Retatrutide demonstrates significant weight lose;
🦠 Hibsago approved for hepatitis B; &
🤢 GLP-1-indicued vomiting reduced with tradipitant.
https://t.co/UA6CqaLXjp

[MPR @eMPR]

The FDA has extended the review period for mitapivat for the treatment of sickle cell disease; the Agency needs additional time to to determine whether a Risk Evaluation and Mitigation Strategy is necessary. https://t.co/Dobtu0DLwY

[MPR @eMPR]

Eli Lilly’s next gen triple hormone receptor agonist, retatrutide, was shown to achieved significantly greater body weight reduction vs Ozempic. https://t.co/lhxEt3pmti

[MPR @eMPR]

Two recent Right of Access cases highlight how noncompliance with patient record access timelines can lead to substantial financial penalties. #LawUpdate https://t.co/1omsOPfMEI

[MPR @eMPR]

Petosemtamab in combination with pembrolizumab shows promised in phase 3 trial as first-line treatment. https://t.co/xnrAHRvWC3

[MPR @eMPR]

Lowering the age of vaccination improves the total number of people protected against HPV, study finds. https://t.co/jLWLH0Dn66

[MPR @eMPR]

If approved, this topical mTOR inhibitor would become the first FDA-approved therapy for children and adults with microcystic lymphatic malformations. https://t.co/WNfSy0azSh

[MPR @eMPR]

Eli Lilly’s next gen triple hormone receptor agonist, retatrutide, was shown to achieved significantly greater body weight reduction vs Ozempic. https://t.co/IPGLRKCmAl

[MPR @eMPR]

Dr Hubert H. Fernandez discusses how the newly approved D1/D5 agonist Juvmo (tavapadon) fits into current treatment paradigms for adult Parkinson disease. https://t.co/u55EwKbSNo

[MPR @eMPR]

Trial results will form the basis for a regulatory submission to use Elrexfio treatment earlier in relapsed or refractory multiple myeloma therapy. https://t.co/dtxPY9WXRr

[MPR @eMPR]

Topline phase 3 data show tradipitant significantly reduced GLP-1–associated vomiting and severe nausea in overweight or obese adults. https://t.co/Cv8ApF09HA

[MPR @eMPR]

Florida’s Hillsborough County remains a dengue hot spot and cooler weather may offer only a short break. #DengueOutbreak https://t.co/1VtqsuLGQh